| Trial ID # | Retrospective Study: Hormonal Maintenance in LGSC |
| Phase | II |
| Drug Class | Hormonal Therapy: Anti-Estrogens |
| Drug Name | Tamoxifen |
| Drugs in Trial | Anastrozole, Letrozole, Tamoxifen |
| Eligible Participant | Stage II-IV low grade serous ovarian cancer after surgery and first-line therapy |
| Patients Enrolled | 203 |
| Therapy Setting | Maintenance |
| Study Design | Open-Label, Non-randomized |
| Endpoints | PFS, OS, evaluated per RECIST or CA125 |
| Efficacy | Hormonal maintenance therapy (HMT)(n=70) vs routine observation (OBS)(n=133): PFS: 64.9 vs 26.4 months (p<0.001) |
| Conclusion | Significantly longer PFS with hormonal maintenance therapy (HMT) vs. observation in Low Grade Serous OC patients |
| Reference | Gershenson DM et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol (2017) 35(10):1103-1111 |